Pediatric Infectious Disease

Register      Login

VOLUME 2 , ISSUE 2 ( April-June, 2020 ) > List of Articles

Antimicrobials

Time to Fight the New with the Old—Old Antibiotics in New Role

Anuradha Vinod, Bhaskar Shenoy

Keywords : Infections, Methicillin-resistant Staphylococcus aureus, Staphylococcus aureus

Citation Information : Vinod A, Shenoy B. Time to Fight the New with the Old—Old Antibiotics in New Role. Pediatr Inf Dis 2020; 2 (2):67-69.

DOI: 10.5005/jp-journals-10081-1242

License: CC BY-NC 4.0

Published Online: 14-10-2020

Copyright Statement:  Copyright © 2020; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Current medical practice is seeing a rise of multidrug-resistant bacteria because of inappropriate antibiotic usage. New antibiotics discoveries are not at par with the rapidly developing drug resistance. To tide over these circumstances, old antibiotics are now being revived researched and assigned new roles. Antibiotics, such as colistin, nitrofurantoin, polymyxin, etc., are used in nosocomial and critical care setting to tackle the multidrug-resistant bacteria. Even the use of old antibiotics should be pathogen centered and inappropriate use should be avoided. In this study, we are trying to throw some light on some of the old antibiotics which are currently in use and their efficacy. A lot of research is still required to optimize the drug dosing and prevention of side effects of these older antibiotics.


PDF Share
  1. Cassir N, Rolain J-M, Brouqui. P. A new strategy to fight antimicrobial resistance: the revival of old antibiotics. Front Microbiol 2014;5:551. DOI: 10.3389/fmicb.2014.00551.
  2. Gupta S, Govil D, Kakar PN, et al. Colistin and polymyxin B: a re-emergence. Indian J Crit Care Med 2009;13(2):49–53. DOI: 10.4103/0972-5229.56048.
  3. Celebi S, Hacimustafaoglu M, Koksal N. Colistimethate sodium therapy for multidrug-resistant isolates in pediatric patients. Pediatr Int 2010;52(3):410–414. DOI: 10.1111/j.1442-200X.2009.03015.x.
  4. Iosifidis E. Colistin administration to pediatric and neonatal patients. Eur J Pediatr 2010;169(7):867–874. DOI: 10.1007/s00431-009-1137-3.
  5. Jajoo M. Intravenous colistin administration in neonates. Pediatr Infect Dis J 2011;30(3):218–221. DOI: 10.1097/INF.0b013e3182064bfe.
  6. Flagas ME. Systemic colistin use in children without cystic fibrosis: a systematic review of the literature. Int J Antimicrob Agents 2009;33:503.e1–50a3.e13.
  7. Falagas ME. Intravenous colistimethate (colistin) use in critically ill children without cystic fibrosis. Pediatr Infect Dis J 2009;28(2):123–127. DOI: 10.1097/INF.0b013e31818a5dbd.
  8. Tamma PD, Newland JG, Pannaraj PS, et al. The use of intravenous colistin among children in the United States: results from a multicenter, case series. Pediatr Infect Dis J 2013;32(1):17–22. DOI: 10.1097/INF.0b013e3182703790.
  9. Siddiqui NR, Qamar FN, Jurair H, et al. Multi-drug resistant gram negative infections and use of intravenous polymyxin B in critically ill children of developing country: retrospective cohort study. BMC Infect Dis 2014;14(1):626. DOI: 10.1186/s12879-014-0626-9.
  10. Huttner A, Verhaegh EM, Harbarth S, et al. Nitrofurantoin revisited: a systematic review and meta-analysis of controlled trials, Mouton. J Antimicrob Chemother 2015;70(9):2456–2464. DOI: 10.1093/jac/dkv147.
  11. Masters PA, O'Bryan TA, Zurlo J, et al. Trimethoprim-sulfamethoxazole revisited. Arch Intern Med 2003;163(4):402–410. DOI: 10.1001/archinte.163.4.402.
  12. Clindamycin: new look at an old drug. Infectious Diseases in Children, January 2005.
  13. Doern GV. Antimicrobial resistance among clinical isolates of streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob Agent Chemother 2001;45(6):1721–1729. DOI: 10.1128/AAC.45.6.1721-1729.2001.
  14. Van Bambeke F. Glycopeptides and glycodepsipeptides in clinical development: a comparative review of their antibacterial spectrum, pharmacokinetics and clinical efficacy. Curr Opin Investigat Drugs 2006;7(8):740–749.
  15. Jeya M, Moon HJ, Lee KM, et al. Glycopeptide antibiotics and their novel semi-synthetic derivatives. Curr Pharm Biotechnol 2011;12(8):1194–1204. DOI: 10.2174/138920111796117382.
  16. Baquero-Artigao F, del Rosal Rabes T. Fosfomycin in the pediatric setting: evidence and potential Indications. J Spanish Soc Chemothe 2019;32(Suppl 1):55–61.
  17. Cross R, Ling C, Day NP, et al. Revisiting doxycycline in pregnancy and early childhood–time to rebuild its reputation? Expert opinion. Drug Saf 2016;15(3):367–382. DOI: 10.1517/14740338.2016.1133584.
  18. Smith K, Leyden JJ. Safety of doxycycline and minocycline: a systematic review. Clin Ther 2005;27(9):1329–1342. DOI: 10.1016/j.clinthera.2005.09.005.
  19. Verboven M, Lauwers S, Pintens H. Temocillin in the treatment of pyelonephritis in children. Drugs Exp Clin Res 1987;113(3):171–173.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.